StemRIM Inc. (JP:4599)
:4599
Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥339.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥18.80B
Enterprise Value¥13.04B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Sep 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-31.14
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Financial FlexibilityNear-zero debt is a durable strength for a biotech with long development cycles: it lowers default risk, reduces fixed financing costs, and preserves optionality to raise or deploy capital when needed. This structural flexibility supports funding R&D or partnering without immediate solvency pressure.
Asset-light Licensing And Collaboration Business ModelA licensing and collaboration model aligns with durable, scalable revenue streams post-approval and lowers capital intensity pre-commercialization. Structural partnership and milestone income can de-risk cash needs versus owning full commercialization, enabling focus on R&D and IP development over heavy manufacturing investments.
Improving Cash-burn Trend While Capital Cushion RemainsAlthough cash flow is negative, the partial improvement in 2025 signals some operational stabilization and, combined with an existing equity buffer, provides a moderate runway. This trend, if sustained, can preserve strategic options for partnering or staged funding over the medium term.
Bears Say
Revenue Collapsed To ZeroA structural disappearance of revenue undermines business sustainability: it implies loss of recurring licensing or product income, eliminates internal funding for R&D, raises dependency on external financing, and reduces visibility for multi-quarter planning—key risks for a developmental biotech.
Large, Persistent Operating Losses And Negative Cash FlowSustained multi-year losses and negative operating/free cash flow materially erode runway and force reliance on fundraising or partnerships. For a biotech, this constrains long-term R&D programs, increases dilution risk, and can weaken negotiating leverage with strategic collaborators.
Erosion Of Equity And Weakening Capital BaseDeclining equity over multiple years indicates the balance sheet is being consumed by losses. This reduces the company's ability to absorb shocks, raises the probability of future dilution or restrictive financing, and diminishes the strategic buffer needed for long, uncertain development timelines.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥339.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥18.80B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Sep 16, 2026 which is in 86 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Jun 10, 2026. The company reported -¥7.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.6.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥7.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.128%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---